Comparison Of Reduced DAPT Followed by P2Y12 Inhibitor Monotherapy With Prasugrel vs stAndard Regimen in STEMI Patients
Status:
Recruiting
Trial end date:
2028-08-01
Target enrollment:
Participant gender:
Summary
The study is a multi-centre, Open-label, Randomized Controlled, 1:1 trial comparing
Prasugrel-based short DAPT (30-45 days) followed by Prasugrel monotherapy versus standard
DAPT regimen in STEMI patients in terms of safety and efficacy endpoints.
In the subgroup of STEMI patients with MVD, a sub-randomization will allow a comparison
between a complete revascularization OCT-guided versus complete revascularization
angiography-guided stent in terms of efficacy and safety endpoints.